FDA approves Herceptin biosimilar as US patent expiresThe FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer Share XFDA approves Herceptin biosimilar as US patent expireshttps://pharmaphorum.com/news/fda-approves-herceptin-biosimilar-as-us-patent-expires/
Janssen to develop Darzalex successor with GenmabJanssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it Share XJanssen to develop Darzalex successor with Genmabhttps://pharmaphorum.com/news/janssen-to-develop-darzalex-successor-with-genmab/
FDA approves Roche’s $90,000 lymphoma combinationThe FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – Share XFDA approves Roche’s $90,000 lymphoma combinationhttps://pharmaphorum.com/news/fda-approves-roches-90000-lymphoma-combination/
Relax criteria to increase sign-ups to cancer trials, says ASCOOnly 3% of patients with cancer in the US enrol on a clinical trial – and the American Share XRelax criteria to increase sign-ups to cancer trials, says ASCOhttps://pharmaphorum.com/news/relax-criteria-to-increase-sign-ups-to-cancer-trials-says-asco/
Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Sanofi trumpets Darzalex rival isatuximab in refractory myelomaSanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 Share XSanofi trumpets Darzalex rival isatuximab in refractory myelomahttps://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/
Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinRoche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – Share XAstellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinhttps://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/
ASCO pilots electronic health record standards to improve cancer careCancer doctors in the US have launched a new scheme that aims to improve care by setting out Share XASCO pilots electronic health record standards to improve cancer carehttps://pharmaphorum.com/news/asco-pilots-electronic-health-record-standards-to-improve-cancer-care/
AZ/Merck & Co wow ASCO with pancreatic cancer dataFinding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the Share XAZ/Merck & Co wow ASCO with pancreatic cancer datahttps://pharmaphorum.com/news/az-merck-co-wow-asco-with-pancreatic-cancer-data/
